Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.37 |
| ▸ | MTOR | P42345 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825943 | 0.91 | PDK2 (0.40) | METPDK2MAP4K4MTORPIK3CA | |
| SCHEMBL826356 | 0.89 | IDH1 (0.38) | MAP4K4DYRK1A | |
| SCHEMBL823770 | 0.83 | MKNK1 (0.40) | METPDK2MAP4K4MTORPIK3CA | |
| SCHEMBL826252 | 0.79 | HPGD (0.40) | MAP4K4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL825895 | 0.78 | MKNK2 (0.34) | MAP4K4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL826101 | 0.78 | MAP4K4 (0.38) | MAP4K4DYRK1A | |
| SCHEMBL826435 | 0.77 | MKNK2 (0.43) | MAP4K4MTOR | |
| SCHEMBL823649 | 0.76 | MEN1 (0.44) | MAP4K4DYRK1A | |
| SCHEMBL825927 | 0.75 | MKNK1 (0.43) | MAP4K4 | |
| SCHEMBL826328 | 0.75 | HDAC4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | claimed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008077649-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | MET 3433/4885PDK2 733/4885MAP4K4 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.